AU2009265099A1 - Sustained release pharmaceutical compositions comprising Quetiapine - Google Patents

Sustained release pharmaceutical compositions comprising Quetiapine Download PDF

Info

Publication number
AU2009265099A1
AU2009265099A1 AU2009265099A AU2009265099A AU2009265099A1 AU 2009265099 A1 AU2009265099 A1 AU 2009265099A1 AU 2009265099 A AU2009265099 A AU 2009265099A AU 2009265099 A AU2009265099 A AU 2009265099A AU 2009265099 A1 AU2009265099 A1 AU 2009265099A1
Authority
AU
Australia
Prior art keywords
dosage form
sustained release
quetiapine
granulation
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009265099A
Other languages
English (en)
Inventor
Ninad Deshpanday
Virendra Ramkrupal Kuril
Sunil Anantrao Mirajkar
Vineeth Raghavan
Avinash Krishnaji Velhal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of AU2009265099A1 publication Critical patent/AU2009265099A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2009265099A 2008-07-01 2009-06-29 Sustained release pharmaceutical compositions comprising Quetiapine Abandoned AU2009265099A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1143KO2008 2008-07-01
IN1143/KOL/2008 2008-07-01
PCT/IN2009/000369 WO2010001413A2 (en) 2008-07-01 2009-06-29 Sustained release pharmaceutical compositions comprising quetiapine

Publications (1)

Publication Number Publication Date
AU2009265099A1 true AU2009265099A1 (en) 2010-01-07

Family

ID=40957738

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009265099A Abandoned AU2009265099A1 (en) 2008-07-01 2009-06-29 Sustained release pharmaceutical compositions comprising Quetiapine

Country Status (6)

Country Link
US (1) US8440223B2 (cg-RX-API-DMAC7.html)
EP (1) EP2309994A2 (cg-RX-API-DMAC7.html)
JP (2) JP2011526622A (cg-RX-API-DMAC7.html)
AU (1) AU2009265099A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010001413A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201100635B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154118A1 (en) 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
TR201104977A1 (tr) 2011-05-23 2012-12-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım gerçekleştiren kaplamaya sahip ketiapin formülasyonu.
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
WO2013095312A1 (en) * 2011-12-19 2013-06-27 Mahmut Bilgic Formulations comprising quetiapine fumarate
US20150231080A1 (en) * 2012-09-10 2015-08-20 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
WO2014155387A1 (en) * 2013-03-24 2014-10-02 Tushar Patel Extended release dosage forms of quetiapine salts
EP2848244A1 (en) 2013-09-16 2015-03-18 Yildiz Özsoy Erginer Extended release tablet formulations of quetiapine
CN104523600A (zh) * 2014-11-21 2015-04-22 哈尔滨圣吉药业股份有限公司 一种富马酸喹硫平缓释微丸及其制备方法
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
JPH0658877A (ja) * 1992-08-11 1994-03-04 Daicel Chem Ind Ltd 酢酸セルロース中のゲル量の評価方法
JP2006219502A (ja) * 1994-04-22 2006-08-24 Astellas Pharma Inc 結腸特異的薬物放出システム
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
JP2002535353A (ja) * 1999-01-29 2002-10-22 ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク 医薬品組成物
WO2005041935A1 (en) 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
AU2006263337A1 (en) * 2005-06-29 2007-01-04 Panacea Biotec Ltd. Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
PL2457563T3 (pl) 2006-05-09 2017-09-29 Mallinckrodt Llc Stałe postacie dawkowania o zmodyfikowanym uwalnianiu rzędu zerowego
US20100056493A1 (en) * 2007-01-25 2010-03-04 Rajesh Jain Modified release pharmaceutical composition and a process of making the same
EP2268283A2 (en) * 2008-03-12 2011-01-05 Dexcel Ltd. Oral modified-release formulations containing thiazepines
US7794750B2 (en) 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
DE202009018024U1 (de) 2008-08-01 2010-12-09 Krka Tovarna Zdravil, D.D., Novo Mesto Quetiapin-Zusammensetzung

Also Published As

Publication number Publication date
WO2010001413A3 (en) 2010-08-12
JP2011526622A (ja) 2011-10-13
ZA201100635B (en) 2011-10-26
US8440223B2 (en) 2013-05-14
US20110151002A1 (en) 2011-06-23
JP2014196334A (ja) 2014-10-16
EP2309994A2 (en) 2011-04-20
WO2010001413A2 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
KR101573889B1 (ko) 속효성과 지속성을 동시에 갖는 약제학적 조성물
US8440223B2 (en) Sustained release pharmaceutical compositions comprising quetiapine in non-gellable polymers
CN102895208B (zh) 包衣片制剂和方法
CN102036654B (zh) 稳定的非典型抗精神病制剂
TWI590835B (zh) 含有氫嗎啡酮(hydromorphone)和納洛酮(naloxone)之藥學組成物
AU2013302359A1 (en) Pharmaceutical compositions of Memantine
WO2010026467A2 (en) Controlled release dosage form of high solubility active ingredient
EP2726064A1 (en) Controlled release oral dosage form comprising oxycodone
AU2004315136A1 (en) Extended release coated microtablets of venlafaxine hydrochloride
US20090264408A1 (en) Extended release dosage forms of quetiapine
US20100003322A1 (en) Enteric coated hydrophobic matrix formulation
AU782059B2 (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
EP1737455A1 (en) Controlled release pharmaceutical composition of tolperisone for oral administration
US20090220593A1 (en) Extended release dosage forms of quetiapine
WO2004096182A1 (en) Extended release matrix tablets of carvedilol
US20150366850A1 (en) Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof
WO2006134610A1 (en) Efavirenz pharmaceutical composition having enhanced dissolution profile
DK2277511T3 (en) Pharmaceutical Compositions of sustained-release Levetiracetam
CA2481377A1 (en) Antihistamine-decongestant pharmaceutical compositions
SK11072000A3 (sk) Tiagabínové prostriedky s predĺženým uvoľňovaním so zníženými vedľajšími účinkami
CA3226799A1 (en) Multiparticulate pharmaceutical composition
WO2026064388A1 (en) Fixed dose combination of flavoxate and alpha-blockers, and formulations and manufacturing processes thereof
US20130273158A1 (en) Extended release compositions of quetiapine
CA2705685A1 (en) Pharmaceutical dosage form containing an antipsychotic agent
WO2015150948A1 (en) Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application